Home/Biosimilar Atlas/Companies/Sanwa Kagaku Kenkyusho

Sanwa Kagaku Kenkyusho

Biosimilar developer, Japan. 1 development product across 1 molecule: darbepoetin alfa.

First approval in the Atlas: Sep 2019, Darbepoetin Alfa BS Sanwa, darbepoetin alfa (PMDA)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Darbepoetin alfaDarbepoetin Alfa BS Sanwa···Sep 2019···1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Sanwa Kagaku Kenkyusho, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Dr. Reddy's LaboratoriesOne shared molecule: darbepoetin alfa6 molecules in its portfolioHeteroOne shared molecule: darbepoetin alfa5 molecules in its portfolioJCR PharmaceuticalsOne shared molecule: darbepoetin alfa3 molecules in its portfolioReliance Life SciencesOne shared molecule: darbepoetin alfa14 molecules in its portfolioViatrisOne shared molecule: darbepoetin alfa2 molecules in its portfolio

Chronology

Compare Sanwa Kagaku Kenkyusho with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.